First documented isolation of Diutina mesorugosa (Candida mesorugosa) from a clinical sample in Argentina
Recent advances in molecular phylogenetic and revisions to the International Code of Nomenclature have led to major changes in the fungal taxonomy. Genus Candida has been subject to extensive reclassification, with ribosomal DNA analysis demonstrating that Candida rugosa represents a cryptic species complex. Consequently, these taxa were reassigned to the novel genus Diutina. The Diutina rugosa complex includes species morphologically and physiologically indistinguishable: D. rugosa, D. mesorugosa, D. neorugosa, and D. pseudorugosa. We report the first case of D. mesorugosa diagnosed in Argentina in a 51-year-old man patient with complete spinal cord syndrome who developed osteomyelitis associated with sacrogluteal pressure ulcers. The yeast was isolated from bone tissue alongside ESBL-producing Proteus mirabilis. Fungal identification was confirmed using ribosomal DNA sequencing. D. mesorugosa is an emerging opportunistic pathogen that affects immunocompromised individuals. The patient responded favorably to a three-month course of oral fluconazole and combination antibiotic therapy (meropenem/ertapenem) for the bacterial co-infection.
Authors
- Constanza Giselle Taverna (ORCID: https://orcid.org/0000-0001-6985-2699)
- Florencia Pastore
- Maximiliano Sortino (ORCID: https://orcid.org/0000-0002-4271-1690)
- Hernán Dalmaso
- Lucía Bulacio
- María Victoria Podestá
- Roberto Parodi
- Silvana Ramadán (ORCID: https://orcid.org/0000-0001-8357-092X)
- Damián Lerman Tenenbaum
- Aranza Sorribas
- Sergio Lera
- Lautaro Calvo
Institutions
- National University of Rosario (AR)
- Administración Nacional de Laboratorios e Institutos de Salud (AR)
- Hospital Provincial de Rosario (AR)
Publication Details
- Journal
- Revista Argentina de Microbiología
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1016/j.ram.2025.11.005
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.00